NCT05575804招募中1 期
Phase Ib/II Study of GQ1001 and Pyrotinib in HER2 Positive Metastatic Breast Cancer Patients Who Had Failed Previous Anti-HER2 Treatment（GRACE）
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Maximum Tolerated Dose (MTD), Phase I
研究概览
简要总结
The aim of this trial is to study the safety, pharmacokinetics and preliminary efficacy of the HER2-targeted antibody-drug conjugate GQ1001 in combination with pyrotinib in patients with HER2-positive metastatic breast cancer patients who had failed previous anti-HER2 treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Having provided written informed consent, and be able to follow clinical trial protocol.
- •Men or women aged 18-
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1，life expectancy greater than 3 months.
- •Left ventricular ejection fraction (LVEF) ≥50%.
- •Histopathological and/or cytological confirmed Her2-positive locally advanced or metastatic breast cancer (IHC3+, or IHC2+ and ISH+), *ISH: Fluorescence in situ hybridization (FISH) or dual in situ hybridization (DISH); ISH positivity is defined as a ratio of HER2 gene copy number to CEP17 signal number ≥2.
- •When the immunohistochemical (IHC) result is 3+, ISH testing is not required. When the IHC result is 2+, ISH testing should be performed to confirm HER2 positivity.
- •Failure for at least 1 line of standard systemic treatment for metastatic disease. Meet one of the following conditions:
- •Recurrent within 12 months after completing or during neoadjuvant/ adjuvant therapy (the regimens contain trastuzumab or its biosimilar with pertuzumab or not).
- •Received at least one treatment with trastuzumab or its biosimilar ±pertuzumab (monotherapy or in combination with other drugs) for recurrent or metastatic disease.
- •Having at least one measurable lesion according to RECIST 1.
- •Previous exposure to taxanes.
- •During the screening period and the first 7 days before treatment, the following indicators confirm appropriate organ functions:
- •Hematology: WBC≥3.0×109/L；NE≥1.5×109/L；Hb≥90 g/L；Plt≥100×109/L;
- •Liver function: Total bilirubin ≤ 1.5 x the upper limit of normal; AST and ALT ≤ 2.5 x the upper limit of normal, ≤ 5.0 x the upper limit of normal in the presence of liver metastases;
- •Kidney function: Serum creatinine ≤1.5 x the upper limit of normal;
- •Coagulation function: prothrombin time and activated partial thromboplastin time ≤1.5 x the upper limit of normal.
- •Adequate wash-out periods:
- •Major surgery ≥4 weeks;
- •Radiotherapy ≥4 weeks (Palliative stereotactic radiotherapy without abdominal involvement radiotherapy: ≥2 weeks);
- •Autologous transplantation: ≥3 months
- •targeted therapy or chemotherapy≥4 weeks;
- •Radioactive particle therapy: ≥3 months
- •Nuclide therapy: ≥3 months
- •Hormone therapy: ≥2 weeks, or based on judgement on the breast cancer
- •Participants from the investigators' judgment;
- •Endocrine therapy: ≥4weeks;
- •Chemotherapy or targeted therapy: 5-fluorouracil-based preparations, folinic acid preparations, and/or Weekly paclitaxel: ≥2 weeks;
- •Tyrosine kinase inhibitor: ≥2 weeks (or 5 half-lives)
- •In the case of a decline period, the longer one shall prevail;
- •Nitrosoureas or mitomycin C: ≥6 weeks
- •Immunotherapy ≥4 weeks;
- •Potent CYP3A4 inhibitor≥3*t1/2 weeks;
- •Any investigational agents≥4 weeks.
- •Female subjects who are capable of bearing children must have negative urine or serum pregnancy test results within 7 days before randomization, and must commit to using contraception throughout the study period and continue to do so for 7 months after the study ends.
排除标准
- •Clinical symptomatic brain metastasis is defined as untreated and symptomatic, or requiring steroid or anticonvulsant treatment to control related symptoms. Patients with asymptomatic brain metastasis, or with stable clinical symptoms and no need for steroid hormone and other treatments for brain metastasis for ≥28 days, can be enrolled.
- •Have previously been treated with: another antibody-drug conjugate (ADC) consisting of DM1 or its derivative，pyrotinib and capecitabine，except for the following situations:
- •During (neo)adjuvant therapy, received pyrotinib, and the participants who have experienced recurrence or metastasis more than 6 months after the last treatment and have not received pirlotinib since then are allowed to be enrolled;
- •Participants who have received pirlotinib treatment during the recurrent and metastatic stage, discontinued the medication due to reasons other than disease progression, and have progressed more than 6 months after discontinuation are allowed to be enrolled;
- •Participants who have received treatment with ADC drugs with different small molecule toxins (such as DS-8201, GQ1005, SHR-A1811, etc.) are eligible for enrollment. Such patients are also allowed to have received pirlotinib treatment during the recurrent or metastatic stage, and those who have progressed after more than 6 months of pirlotinib treatment are also eligible for enrollment.
- •Have other malignant tumors within 5 years before signing the informed consent form ( except for cured skin basal cell carcinoma and cervical carcinoma in situ).
- •Have a medical history of myocardial infarction or clinically significant heart diseases, including but not limited to,
- •symptomatic congestive heart failure (CHF) (NYHA classes II-IV), or serious cardiac arrhythmia which required to therapy;
- •Having a history of myocardial infarction or unstable angina pectoris within 6 months prior to the initial treatment,
- •Have a corrected QT interval (QTc) prolongation to > 450 milliseconds (ms) in males and > 470 ms in females.
- •Have clinically significant acute and chronic pulmonary diseases (e.g. interstitial lung disease (ILD), lung infection, pulmonary fibrosis, and severe radiation pneumonitis), participants with a history of ILD/non-infectious pneumonia requiring hormone therapy, or suspected of having lung diseases based on imaging examination at screening, with imaging suggesting miliary disseminated metastasis, subjects with specific pulmonary complications including but not limited to any potential lung diseases (such as pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, or other conditions that may interfere with the detection or management of drug-related pulmonary toxicity within 3 months prior to enrollment in the study), or subjects requiring oxygen therapy.
- •History of allergic reaction to any component of GQ
- •The toxicity of previous anti-cancer therapy has not recovered to ≤1 as specified in CTCAE v5.0 (except for hair loss); e.g. chronic grade 2 toxicity might be determined per the investigator's judgment.
- •The cumulative dose of anthracyclines or equivalent>500 mg/m
- •Uncontrollable infections require intravenous antibiotics, antiviral drugs, or antifungal drugs.
- •Hepatitis B virus (HBV) infection (including hepatitis B surface antigen [HBsAg] positive or hepatitis B core antibody [HBcAb] positive and HBV DNA positive); HIV, syphilis, hepatitis C antibody positive, or other severe and fatal viral or bacterial diseases, except for patients with stable hepatitis B (HBV viral copy number below the upper limit of reference value) after drug treatment and cured hepatitis C patients (HCV viral copy number below the detection limit of assay method).
- •Per the investigator's judgment, participants with any history or current evidence of concomitant disease treatment or laboratory abnormalities may interfere with the trial results, as well as their participation and compliance.
- •Lactating women or women who have confirmed pregnancy through a pregnancy test within 7 days prior to their first treatment.
- •Male or female subjects unwilling to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) during the study and for 7 months following the last dose of the study drug infusion.
- •Other circumstances that are deemed not appropriate for the study.
- •Inability to swallow, chronic diarrhea and intestinal obstruction, or other factors that affect drug administration and absorption.
研究组 & 干预措施
experimental group
Experimental
Patients will receive the recommended phase II dose of GQ1001 determined in phase I. GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity.
干预措施: GQ1001+pyrotinib (Drug)
结局指标
主要结局
Maximum Tolerated Dose (MTD), Phase I
时间窗: From the first dose to the end of Cycle 1, 21 days
Highest administered dose with \< 33% of participants experiencing dose-limiting toxicity (DLT) in the first 6 DLT evaluable participants.
Dose-limiting toxicities (DLTs), Phase I
时间窗: From the first dose to the end of Cycle 1, 21 days
Side effects of drug or treatment that are serious enough to prevent an increase in dose or level of that treatment, according to NCI-CTCAE Version 5.0.
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
时间窗: up to 24 months
Incidence and severity of Treatment-emergent adverse events, treatment-related adverse events and serious adverse events, according to NCI-CTCAE Version 5.0 (The number of participants who had treatment-related side effects in the population who had received one therapy at least).
Objective Response Rate (ORR), Confirmed by the researcher's evaluation, Phase II
时间窗: up to 24 months
The objective response rate will be analyzed according to the RECIST 1.1 standard tumor evaluation.
次要结局
- Duration of Response (DoR)(up to 24 months)
- Trough Serum concentration (Cthough), Phase I(At the end of Cycle 3 (each cycle is 21 days))
- Maximum Serum Concentration (Cmax), Phase I(At the end of Cycle 3 (each cycle is 21 days))
- Area Under the Concentration-time Curve (AUC), Phase I(At the end of Cycle 3 (each cycle is 21 days))
- Disease Control Rate (DCR)(up to 24 months)
- Objective Response Rate (ORR), Phase I(up to 24 months)
- PFS(up to 24 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast CancerBreast CancerNCT01937689Jiangsu HengRui Medicine Co., Ltd.40
招募中
1 期
Phase I clinical study on the safety of HER2-specific chimeric antigen receptor (CAR) gene-modified T cell therapyHER2 positive osteosarcoma/soft tissue sarcoma and gynecologic malignancyJPRN-jRCT2033220088Yozo Nakazawa12
已完成
1 期
Immunotherapy Vaccine and Herceptin in Breast CancerBreastcancerNCT03014076Cancer Insight, LLC30
Unknown
2 期
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast CancerMetastatic Breast CancerNCT01283789University of Kansas Medical Center23
招募中
2 期
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 SignalingBreast CancerNCT04965064University of Rochester22